header-news
Drug regime gets phase II trials
Wednesday, 16 January 2008
A new drug treatment regime for patients living with different forms of lymphoma is undergoing phase II clinical trials in the US, it has been announced.

Drug firms Pharmion Corporation and MethylGene are examining how two of their drugs - Pharmion's Vidaza and Methyl's MGCD0103 - perform when given to patients with relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma.
Read more...
 
Heart attack drug trials to launch
Tuesday, 15 January 2008
Phase IIb trials of a medicine designed to prevent heart attacks are to begin in the spring after positive results from phase IIa trials.

Drugmaker DeCode Genetics revealed that it plans to enrol 400 subjects in a new trial designed to collect data on "its pharmacokinetic and pharmacodynamic parameters, as well as safety and tolerability".
Read more...
 
Colorectal cancer enters phase II trials
Monday, 14 January 2008
A new drug designed to treat patients with colorectal cancer is to undergo phase IIb trials later this year, it has been announced.

Nektar Therapeutics said that NKTR-102, an irinotecan, will be examined at more than 40 centres across the world in order to collect data on its safety and efficacy when used to treat patients who have solid tumours in the bowel or rectum.
Read more...
 
Drug undergoes tests in two separate trials
Friday, 11 January 2008
Two separate phase II clinical trials have been launched to test the efficacy, safety and tolerability of a new drug when it is given to patients with one of two different medical conditions.

XenPort intends to examine the performance of its XP19986 medicine when taken by patients who are suffering with gastroesophageal reflux disease (GERD) or spasticity due to spinal cord injury.
Read more...
 
More...
<< Start < Prev 1 2 Next > End >>

Results 1 - 24 of 46